

A18. Fair value information (continued)

	Fair value of financial instruments carried at fair value Level 1 RM'000	Fair value of financial instruments not carried at fair value Level 3 RM'000	Total fair value RM'000	Carrying amount RM'000
Audited				
31.12.2021				
Financial assets				
Investment in financial assets	4,632	-	4,632	4,632
Financial liabilities				
Term loans	-	(8,925)	(8,925)	(8,317)
Hire purchase liabilities	-	(7,807)	(7,807)	(7,491)
	-	(16,732)	(16,732)	(15,808)

Policy on transfer between levels

The fair value of an asset to be transferred between levels is determined as of the date of the event or change in circumstances that caused the transfer.

Level 1 fair value

Level 1 fair value is derived from quoted price (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.

Level 3 fair value

Level 3 fair value is estimated using unobservable inputs for the financial assets and liabilities.

The following table shows the valuation techniques used in the determination of fair values within Level 3, as well as the key unobservable inputs used in the valuation models.

Type	Description of valuation technique and inputs used
Term loans and hire purchase liabilities	Discounted cash flows using a rate based on the current market rate of borrowing of the respective entities at the reporting date.

PART B - EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF MAIN MARKET LISTING REQUIREMENT OF BURSA MALAYSIA SECURITIES BERHAD

B1. Review of financial performance

(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income

Current financial quarter against corresponding financial quarter

	Unaudited Individual quarter ended 31 December		Variance %
	2022 RM'000	2021 RM'000	
Revenue	28,413	26,607	6.79
Profit before tax ("PBT")	<u>5,698</u>	<u>6,335</u>	(10.06)

The Group reported revenue of RM28.41 million for the current financial quarter under review. This represents an increase in revenue of approximately 6.79% against the corresponding financial quarter where revenue amounted to approximately RM26.61 million.

The slight increase in revenue by comparing to the corresponding financial quarter is mainly due to the easing and relaxation of certain restrictions under the Government of Malaysia's National Recovery Plan ("NRP") in controlling the coronavirus disease ("**COVID-19**") pandemic while progressively reopening society and the economy towards the new normal, there was an increase in the number of patients seeking treatments, including patients for refractive surgeries and cataract surgeries who had postponed their treatments during the various movement control orders implemented within Malaysia.

Besides that, ongoing promotions for eye specialist services through online platforms have sustained the momentum in the increase in revenue during the current financial quarter under review as compared to the corresponding financial quarter.

B1. Review of financial performance (continued)**(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (continued)****Current financial quarter against corresponding financial quarter (continued)**

In terms of geographical segmentation (as tabulated below), the Group recorded increase in revenue for all geographical segments.

	Unaudited Individual quarter ended 31 December		Variance %
	2022	2021	
	RM'000	RM'000	
Revenue			
North Malaysia	4,658	5,161	(9.75)
Central Malaysia	17,048	15,986	6.64
South Malaysia	5,674	4,947	14.70
East Malaysia	1,033	513	101.36
	<u>28,413</u>	<u>26,607</u>	

While the Group's revenue for the current financial quarter under review increased by 6.79% as compared to the corresponding financial quarter, the Group's PBT decreased by 10.06% (from RM6.35 million to RM5.70 million). The decrease in PBT was mainly due to an increase in staff costs, as an additional performance bonus was given out to staff.

B1. Review of financial performance (continued)**(a) Highlight on Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (continued)****Current financial period against corresponding financial period**

	Unaudited		Variance %
	Cumulative quarter ended 31 December		
	2022 RM'000	2021 RM'000	
Revenue	108,041	88,898	21.53
PBT	23,505	18,591	26.43

The Group reported revenue of RM108.04 million for the current financial period, as compared to RM88.90 million in the corresponding financial period, representing an increase of RM19.14 million or 21.53%.

With the easing and relaxation of certain restrictions under the Government of Malaysia's National Recovery Plan ("NRP") in controlling the coronavirus disease ("COVID-19") pandemic while progressively reopening society and the economy towards the new normal, there was an increase in the number of patients seeking treatments, including patients for refractive surgeries and cataract surgeries who had postponed their treatments during the various movement control orders implemented within Malaysia.

In terms of geographical segmentation (as tabulated below), the Group recorded increase in revenue for all geographical segments.

	Unaudited		Variance %
	Cumulative quarter ended 31 December		
	2022 RM'000	2021 RM'000	
Revenue			
North Malaysia	19,083	13,734	38.95
Central Malaysia	62,202	58,240	6.80
South Malaysia	23,280	15,187	53.29
East Malaysia	3,476	1,737	100.12
	<u>108,041</u>	<u>88,898</u>	